PolymarketVerificar disponibilidadeSem KYC2% de taxaDados de resolução verificadosRazoavelmente calibrado
Probabilidade implícita atual
December 31, 68%+1.0pt
Qualidade do mercado
67 / 100
Qualidade média
Volume 24h
1,9 mil €
Liquidez
16,9 mil €
Liquidez média
Compra / Venda
67.0% / 68.0%
Spread
1.0 pt
Spread apertado
Comments
0
Dados do mercado
Atualizado há 15 minutos
19/08/26, 17:4931/12/27, 23:59
Tendências
Resultado24hProbabilidade
Regras
This market will resolve to "Yes" if the U.S. Food and Drug Administration (FDA) grants approval of intismeran autogene for any indication by December 31, 2027, 11:59 PM ET.
Otherwise, this market will resolve to "No".
Intismeran autogene refers to the individualized neoantigen therapy developed by Moderna and Merck and evaluated in the Phase 3 INTerpath-001 trial (NCT05933577), also known as mRNA-4157 and V940, together with any brand, trade, or nonproprietary name later assigned to that product, as well as any renamed or modified version that the relevant company or the FDA identify as the same product or a direct continuation of the V940/mRNA-4157 program.
Differences in neoantigen composition between patients will not affect resolution.
Changes to the product's formulation will not affect resolution, provided the FDA approves the product described above.
Approval as part of a combination regimen will qualify.
Quais são as probabilidades atuais de FDA approves skin cancer vaccine by which date??
A Polymarket cota December 31, em 68% em 21 de agosto de 2026.
Quando FDA approves skin cancer vaccine by which date? é resolvido?
FDA approves skin cancer vaccine by which date? deverá ser resolvido em 31 de dezembro de 2027.
Como FDA approves skin cancer vaccine by which date? é liquidado?
A Polymarket liquida este mercado da seguinte forma: This market will resolve to "Yes" if the U.S. Food and Drug Administration (FDA) grants approval of intismeran autogene for any indication by December 31, 2027, 11:59 PM ET.